Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 6/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.50 |
| ▸ | CCKAR | P32238 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17254230 | 0.92 | PAX8 (0.53) | MMP1MMP3MMP9CA1CA2 | |
| SCHEMBL17232586 | 0.92 | PAX8 (0.53) | MMP1MMP3MMP9CA1CA2 | |
| SCHEMBL22343025 | 0.89 | PAX8 (0.48) | CCKBROPRD1CCKARMMP1MMP3 | |
| SCHEMBL13956678 | 0.89 | PAX8 (0.52) | MMP1MMP3MMP9CA1CA2 | |
| SCHEMBL21981319 | 0.88 | REN (0.53) | MMP1MMP3MMP9PAX8TDP1 | |
| SCHEMBL21981320 | 0.88 | REN (0.53) | MMP1MMP3MMP9PAX8TDP1 | |
| SCHEMBL17553458 | 0.88 | PAX8 (0.52) | CCKBRMMP1MMP3MMP9CA1 | |
| SCHEMBL1755615 | 0.88 | TDP1 (0.61) | MMP1MMP3MMP9CA1CA2 | |
| SCHEMBL17254256 | 0.87 | TDP1 (0.56) | MMP1MMP3MMP9CA1CA2 | |
| SCHEMBL23352495 | 0.86 | REN (0.56) | PAX8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993629-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2024-05-28 | — | — | US | disclosed |
| US-20220106355-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993629-B2 | Method for producing peptide compound | VIP, NGLY1, IAPP | CCKBR 13/4885OPRD1 2975/4885CCKAR 50/4885 |
| US-20220106355-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | VIP, NGLY1, IAPP | CCKBR 13/4885OPRD1 2975/4885CCKAR 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.